SCHEMBL3470599

SCHEMBL3470599

COC(=O)c1ccc(OC(C)OC)c(OC)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.64
KMT2A Q03164 5/20 0.57
TSHR P16473 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
MEN1 O00255 2/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
LMNA P02545 1/20 0.50
ATM Q13315 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GLA P06280 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6568018 0.89 MAPT (0.66) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL6276416 0.86 MAPT (0.62) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL3132688 0.86 MAPT (0.62) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL5755306 0.84 MAPT (0.60) MAPTKMT2ATSHRCYP1A2CYP3A4
Veratric Acid Methyl Ester SCHEMBL2050732 0.84 MAPT (0.86) MAPTKMT2ATSHRCYP1A2CYP3A4
Veratric Acid Methyl Ester SCHEMBL29573244 0.84 MAPT (0.86) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL3738587 0.84 MAPT (0.64) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL18031241 0.83 MAPT (0.59) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL6622310 0.83 MAPT (0.59) MAPTKMT2ATSHRCYP1A2CYP3A4
SCHEMBL20630574 0.83 MAPT (0.59) MAPTKMT2ATSHRCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102746242-A Synthesis method of 6, 7-substituent-4-aniline quinazoline OMEGA CO LTD 2012-10-24 CN disclosed
CN-101863844-B Synthesis method of 6, 7-substituent-4-aniline quinazoline XIANGZHEN BIOLOGY TECHNOLOGY CO LTD 2012-10-03 CN disclosed
US-20100267949-A1 Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline OMEGA MEDICAL TAIWAN LIMITED (TW) 2010-10-21 US disclosed
CN-101863844-A Synthesis method of 6, 7-substituent-4-aniline quinazoline XIANGZHEN BIOLOGY TECHNOLOGY CO LTD 2010-10-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267949-A1 Method of Synthesizing 6,7-Substituted 4-Anilino Quinazoline NQO2, ATIC, CYP3A7 MAPT 3826/4885KMT2A 2686/4885TSHR 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.